Literature DB >> 17062704

Genomics and proteomics of bone cancer.

Aaron G Marguiles1, V Suzanne Klimberg, Sudeepa Bhattacharrya, Dana Gaddy, Larry J Suva.   

Abstract

Although the control of bone metastasis has been the focus of intensive investigation, relatively little is known about the molecular mechanisms that regulate or predict the process, even though widespread skeletal dissemination is an important step in the progression of many tumors. As a result, understanding the complex interactions contributing to the metastatic behavior of tumor cells is essential for the development of effective therapies. Using a state-of-the-art combination of gene expression profiling and functional annotation of human tumor cells, and surface-enhanced laser desorption/ionization time-of-flight mass spectrometry of patient serum, we have shown that changes in tumor biochemistry correlate with disease progression and help to define the aggressive tumor phenotype. Based on these approaches, it is apparent that the metastatic phenotype of tumor cells is extremely complex. The identification of the phenotype of tumor cells has benefited greatly from the application of gene expression profiling (microarray analysis). This technology has been used by many investigators to identify changes in gene expression and cytokine and growth factor elaboration (such as interleukin 8). The tumor phenotype(s) presumably also include changes in the cell surface carbohydrate profile (via altered glycosyltransferase expression) and heparan sulfate expression (via increased heparanase activity), to name but a few. These specific alterations in gene expression, identified by functional annotation of accumulated microarray data, have been validated using a variety of approaches. Collectively, the data described here suggest that each of these activities is associated with distinct aspects of the aggressive tumor cell phenotype. Collectively, the data suggest that multiple factors constitute the complex phenotype of metastatic tumor cells. In particular, the differences observed in gene expression profiles and serum protein biomarkers play a critical role in defining the mechanisms responsible for bone-specific colonization and growth of tumors in bone. Future studies will identify the mechanisms that participate in the formation of secondary tumor growths of cancers in bone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17062704     DOI: 10.1158/1078-0432.CCR-06-1070

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

1.  Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma.

Authors:  Paul B Romesser; David H Perlman; Douglas V Faller; Catherine E Costello; Mark E McComb; Gerald V Denis
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

Review 2.  Mechanisms of bone metastases of breast cancer.

Authors:  Larry J Suva; Robert J Griffin; Issam Makhoul
Journal:  Endocr Relat Cancer       Date:  2009-05-14       Impact factor: 5.678

Review 3.  Optimal management of bone metastases in breast cancer patients.

Authors:  Mh Wong; N Pavlakis
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-05-02

4.  Serum biomarker profile associated with high bone turnover and BMD in postmenopausal women.

Authors:  Sudeepa Bhattacharyya; Eric R Siegel; Sara J Achenbach; Sundeep Khosla; Larry J Suva
Journal:  J Bone Miner Res       Date:  2008-07       Impact factor: 6.741

5.  Biomarkers for Bone Tumors: Discovery from Genomics and Proteomics Studies and Their Challenges.

Authors:  Wan I Wan-Ibrahim; Vivek A Singh; Onn H Hashim; Puteri S Abdul-Rahman
Journal:  Mol Med       Date:  2015-11-13       Impact factor: 6.354

Review 6.  Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice.

Authors:  Bob T Li; Matthew H Wong; Nick Pavlakis
Journal:  J Clin Med       Date:  2014-01-09       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.